Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (now known as REVVITY, INC.) on December 19, 2017. The report details the completion of a major acquisition event.
Key Financial Metrics
Acquisition Cost: Approximately €1,200,000,000 (total net purchase price).
Ownership Stake Acquired: 99.7% of the outstanding equity interests of EUROIMMUN Medizinische Labordiagnostika AG.
Payment Method: Cash.
Other Metrics: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. Pro forma financial information and financial statements of the acquired business are not included in this filing.
Material Changes
- Asset Acquisition: PerkinElmer, Inc., through its subsidiary PerkinElmer Germany Diagnostics GmbH, completed the acquisition of EUROIMMUN Medizinische Labordiagnostika AG.
- Shareholder Structure: The transaction involved purchasing the majority equity interest held by the Controlling Shareholder (Prof. Dr. Winfried Stöcker) and Stöcker KG, as well as exercising options to acquire shares from other shareholders at the same price per share.
- Corporate Structure: As of December 19, 2017, EUROIMMUN became an indirect subsidiary of PerkinElmer, Inc.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the transaction was executed pursuant to the Share Sale and Transfer Agreement dated June 16, 2017, and amended thereafter.
Regulatory Filings: Required financial statements and pro forma financial information are not filed herewith but will be submitted to the SEC via amendment within 71 days of the filing date.
Risks and Contingencies: The text does not explicitly list new risks or contingencies arising from this specific event, other than the standard incorporation by reference of the Transfer Agreement.
Investor Verification Checklist
- Verify the final purchase price of €1,200,000,000 and the exchange rate impact on USD financial statements.
- Review the upcoming amendment to this 8-K (due within 71 days) for the required pro forma financial information and financial statements of EUROIMMUN.
- Examine the full text of the Share Sale and Transfer Agreement (Exhibit 2.1) for specific covenants, earn-outs, or contingent liabilities.
- Confirm the integration timeline and expected synergies in subsequent earnings releases or 10-K filings.